Monitor the final pricing and size of the offering, which will determine the degree of dilution. The casdatifan data provides a positive catalyst, but the capital raise signals near-term cash needs despite a $694M cash position.
Price Chart
Executive Summary
Arcus Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock, with the size and price left as placeholders. The filing follows a same-day 8-K disclosing ~$694M in cash as of September 30, 2026, and positive Phase 2 data for its lead candidate casdatifan in ccRCC. The offering will dilute existing holders, but proceeds are earmarked to accelerate casdatifan's clinical development.
Key Facts
- Preliminary prospectus supplement for an underwritten common stock offering; share count and price are undisclosed placeholders.
- Underwriters include Jefferies, Leerink Partners, and TD Cowen, with a 30-day option for additional shares.
- Proceeds intended to fund R&D, including expansion and acceleration of casdatifan clinical program.
- Same-day 8-K reported preliminary cash of ~$694M as of September 30, 2026.
- Positive Phase 2 ARC-20 data for casdatifan in ccRCC presented on October 20, 2026.
- Net tangible book value as of June 30, 2026 was $463.2M, or $3.65 per share.
- 127,018,631 shares outstanding as of June 30, 2026, with significant overhang from options and RSUs.
Financial Impact
Offering size and price are undisclosed; dilution will reduce per-share metrics for existing holders.
Risk Factors
- Dilution from the offering and potential exercise of underwriter option.
- Execution risk in casdatifan clinical program and regulatory path.
- Potential for further equity raises if cash runway proves insufficient.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-427888 |
| Document: 0001193125-26-427888-index-headers.html | 0001193125-26-427888 |
| Document: 0001193125-26-427888-index.html | 0001193125-26-427888 |
| Document: 0001193125-26-427888.txt | 0001193125-26-427888 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $18.47 | awaiting T+1 | — | $18.54 (−0.38%) |
Oct 22, 2026 3d ago | 424B5 | $19.36 | awaiting T+1 | — | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 424B5 | $19.36 $18.54 | ▲ +4.24% | ▲ +3.71% | $18.54 (+4.24%) |
Oct 21, 2026 4d ago | 8-K | $19.36 $18.54 | ▼ −4.24% | ▼ −3.71% | $18.54 (−4.24%) |
Oct 20, 2026 6d ago | 8-K | $23.75 $19.10 | ▼ −19.58% | ▼ −20.10% | $18.54 (−21.94%) |
Jul 9, 2026 15w ago | 144 | $28.92 $28.07 | ▼ −2.94% | ▼ −2.17% | $18.54 (−35.89%) |
Apr 21, 2026 26w ago | DEFA14A | $26.62 $25.13 | ▼ −5.60% | ▼ −5.20% | $18.54 (−30.35%) |
Apr 20, 2026 27w ago | 8-K | $22.74 $24.52 | ▼ −7.83% | ▼ −8.48% | $18.54 (+18.47%) |
Apr 8, 2026 28w ago | 144 | $23.28 $22.34 | ▼ −4.04% | ▼ −3.98% | $18.54 (−20.36%) |
Feb 25, 2026 34w ago | 8-K | $19.54 $20.37 | ▲ +4.25% | ▲ +4.73% | $18.54 (−5.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers